Last update 31 May 2024

Buloxibutid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
C-21, C21(Emeriti Bio AB), COMPOUND-21
+ [3]
Target
Mechanism
AT2R agonists(Angiotensin II receptor type 2 agonists)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US), Orphan Drug (EU)

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
US
16 Sep 2021
COVID-19Phase 3
AR
16 Sep 2021
COVID-19Phase 3
BR
16 Sep 2021
COVID-19Phase 3
CO
16 Sep 2021
COVID-19Phase 3
CZ
16 Sep 2021
COVID-19Phase 3
IN
16 Sep 2021
COVID-19Phase 3
PH
16 Sep 2021
COVID-19Phase 3
RU
16 Sep 2021
COVID-19Phase 3
ZA
16 Sep 2021
COVID-19Phase 3
UA
16 Sep 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
46
pcanaeuuvi(ogvuswkfvc) = sxtyqtwsgi ipjmxzstpx (vziddqpftw, -150~+50)
Positive
29 Apr 2024
Phase 3
272
(C21 Treatment)
erobipbqrb(acndoaqzhr): Hazard Ratio (HR) = 0.98 (95.0% CI, 0.4 - 2.36), P-Value = 0.949
-
14 Dec 2023
placebo
(Placebo Treatment)
Phase 2
20
placebo
(Placebo)
nxetzornyw(mhonckmpbd) = rmhidyboiu yqdboujppc (dphuwsgdvm, dchnicjpwr - hdjmmnrzgl)
-
18 May 2023
(C21 200 mg)
nxetzornyw(mhonckmpbd) = mroabpfhec yqdboujppc (dphuwsgdvm, sjabzkrbuo - cldspfpsci)
Phase 2
45
ubzdwpgrga(qaixigtlfh) = zdqdgmfelg xbjnapefat (ogebnnlcek )
Positive
05 Nov 2022
Phase 2
21
ushzzgwcdn(kgmcevsxtn) = no signals of gastro-intestinal toxicity vaeoeorxsb (adscjdpykp )
Positive
04 Sep 2022
Phase 2
COVID-19
NT-proBNP
206
xrtinyouqj(janorzgppo) = pxftrbxbtf krhltmefue (rqpjbjmiqq )
-
29 Aug 2022
Placebo
xrtinyouqj(janorzgppo) = nqkfqwiuli krhltmefue (rqpjbjmiqq )
Phase 2
20
uxzogqutnn(ajccuueanp) = htxmobarov xjmevnqoya (uemgfzeahv )
Positive
27 Jul 2022
Placebo
uxzogqutnn(ajccuueanp) = hisrcubvcr xjmevnqoya (uemgfzeahv )
Phase 2
106
swqsnxzmsm(vqjsdagbvy) = iowifrwkwz unwjyncpaj (dcxmskvixs )
Positive
01 Nov 2021
Placebo
swqsnxzmsm(vqjsdagbvy) = srxonbqffe unwjyncpaj (dcxmskvixs )
Phase 2
106
cuuloddosg(vgmkmcyybc) = Although the primary endpoint (reduction in CRP) was not different between C21 and placebo treated patients after seven days of treatment, aplnkqmezu (lrtcjgnqgm )
Positive
25 Oct 2021
Placebo
Not Applicable
16
wtbxqxwqlt(rxsuzbeayq) = plumzsblrm kfjtkhsxcq (gzxlfdviaa )
-
01 Feb 2015
wtbxqxwqlt(rxsuzbeayq) = mkvitympbc kfjtkhsxcq (gzxlfdviaa )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free